These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23158996)

  • 1. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
    Li Q; Xu T; Wang XF
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
    Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
    J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postoperative intravesical instillation of THP for superficial bladder tumor: clinical results of prophylactic effects on the recurrence. Fukushima THP Research Group].
    Aikawa K; Irisawa C; Muraki O; Yamaguchi O; Shiraiwa Y; Noguchi M; Koguchi M; Yokoyama J; Ito K; Kumakawa K
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):509-13. PubMed ID: 1558401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
    Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
    BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of prophylactic intravesical instillation of pirarubicin to prevent recurrent bladder tumors following nephroureterectomy for upper urinary tract cancer].
    Nagashima M; Araki A; Yanagisawa M; Komiya A; Takano T; Murakami T; Ikeda I
    Hinyokika Kiyo; 2013 Apr; 59(4):213-6. PubMed ID: 23635455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
    Hashimura T; Shirahase T; Inoue T; Yamasaki T; Terada N; Ogura K; Arai Y; Hida S; Ueda T
    Hinyokika Kiyo; 2005 Jul; 51(7):439-42. PubMed ID: 16119805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
    Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
    Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
    Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
    Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
    Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
    Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical investigation on intravesical instillation of high-dose pirarubicin during perioperative period to prevent bladder carcinoma recurrence].
    Gao JG; Tian T; Song YL; Dong ZY; Yang XF
    Zhonghua Wai Ke Za Zhi; 2010 Nov; 48(21):1650-2. PubMed ID: 21211262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.